Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...
The ARASAFE study showed significant reductions in grade 3-5 adverse events and grade 3-4 neutropenia or death with a 50 ...
Belzutifan, pembrolizumab, and lenvatinib combination showed superior efficacy in advanced ccRCC, with high overall response rates and prolonged progression-free survival. Arm 4 demonstrated a median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback